X
[{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korean Investment Partners","pharmaFlowCategory":"D","amount":"$22.2 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*line Pharma Raises \u20ac20 Million in Series B Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","amount":"$20.3 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*Line Pharma Raises \u20ac17.5 Million ($20.3M) In Series B2 Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PDC*line Pharma Presents First Immunological Results From Phase I\/II Trial With PDC*lung01 at ESMO-IO 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"PDC*line Pharma","sponsor":"BioWin","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"PDC*line Pharma and Partners Receive \u20ac8.1M from Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by PDC Line Pharma
Filters
Companies By Therapeutic Area
Details:
The net proceeds will be used to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
Lead Product(s):
Dendritic Cell-based Vaccine
Therapeutic Area: Oncology
Product Name: PDC*Neo
Highest Development Status: Preclinical
Product Type: Vaccine
Partner/Sponsor/Collaborator:
BioWin
Deal Size: $8.9 million
Upfront Cash: Undisclosed
Deal Type: Financing
January 17, 2024
Details:
Results showed that in a large proportion of subjects PDC*lung01, in monotherapy and combined with pembrolizumab, induces a significant expansion of effector memory CD8+ T-cells specific to the tumor peptides carried by PDC*lung01.
Lead Product(s):
PDC*lung01,Pembrolizumab
Therapeutic Area: Oncology
Product Name: PDC*lung01
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 08, 2022
Details:
Proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer associated with or not with anti-PD-1 treatment in NSCLC.
Lead Product(s):
PDC*lung01,Pemetrexed
Therapeutic Area: Oncology
Product Name: PDC*lung01
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Korea Investment Partners
Deal Size: $20.3 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
December 06, 2021
Details:
Funding will support company’s phase I/II trial with PDC*lung01 candidate in lung cancer.
Lead Product(s):
PDC lung01
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Korean Investment Partners
Deal Size: $22.2 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
January 22, 2020